Mogrify Ltd

Generation of chondrocytes by cell conversion for regenerative medicine applications

Funding £881,397
Competition Improving Outcomes in Musculoskeletal Disorders
Competition Date Autumn 2019
Local AHSN Please Select
Website https://mogrify.co.uk/
Key Contact Dr. Karin Schmitt – Chief Business Officer
Status In Development

Technology Biotechnology

Mogrify™ has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.

Mogrify is leveraging this technology to identify small molecules capable of converting expandable cell types into chondrocytes in order to create a scalable supply of allogeneic chondrocytes for use in regeneration of the joints in cartilage defects and osteoarthritis.